A Prognostic Signature for Colon Adenocarcinoma Patients Based on m6A-Related lncRNAs

Su-Zhe Zhou; Ying-Lian Pan; Qing-Chun Deng; Chang-Jun Yin; De-Jiang Zhou; Ming-Liang Liu; Jun Zhou; Xiao-Jing Wu

doi:10.1155/2023/7797710

A Prognostic Signature for Colon Adenocarcinoma Patients Based on m6A-Related lncRNAs

J Oncol. 2023 Feb 13:2023:7797710. doi: 10.1155/2023/7797710. eCollection 2023.

Authors

Su-Zhe Zhou¹, Ying-Lian Pan², Qing-Chun Deng³, Chang-Jun Yin⁴, De-Jiang Zhou⁴, Ming-Liang Liu⁵, Jun Zhou^{4

6}, Xiao-Jing Wu⁷

Affiliations

¹ Department of General Practice, Hefei BOE Hospital, Hefei 230013, China.
² Department of Medical Oncology, The First Affiliated Hospital of Hainan Medical University, Haikou 570102, China.
³ Department of Gynecology, The Second Affiliated Hospital of Hainan Medical University, Haikou 570102, China.
⁴ Department of Gastrointestinal Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou 510120, China.
⁵ Department of Gastrointestinal Surgery, Affiliated Hospital of Jining Medical College, Jining 272007, China.
⁶ Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China.
⁷ Department of Surgery Critical Care Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

Abstract

N6-methyladenosine (m6A) modification is a common epigenetic modification. It is reported that lncRNA can be regulated by m6A modification. Previous studies have shown that lncRNAs associated with m6A regulation (m6A-lncRNAs) serve as ideal prognostic biomarkers. However, whether lncRNAs are involved in m6A modification in colon adenocarcinoma (COAD) needs further exploration. The objective of this study was to construct an m6A-lncRNAs-based signature for patients with COAD. We obtained the RNA sequencing data and clinical information from The Cancer Genome Atlas (TCGA). Pearson correlation analysis was employed to recognize lncRNAs associated with m6A regulation (m6A-lncRNAs). 24 prognostic m6A-lncRNAs was identified by univariate Cox regression analysis. Gene set enrichment analysis (GSAE) was used to investigate the potential cellular pathways and biological processes. We have also explored the relationship between immune infiltrate levels and m6A-lncRNAs. Then, a predictive signature based on the expression of 13 m6A-lncRNAs was constructed by the Lasso regression algorithm, including UBA6-AS1, AC139149.1, U91328.1, AC138207.5, AC025171.4, AC008760.1, ITGB1-DT, AP001619.1, AL391422.4, AC104532.2, ZEB1-AS1, AC156455.1, and AC104819.3. ROC curves and K M survival curves have shown that the risk score has a well-predictive ability. We also set up a quantitative nomogram on the basis of risk score and prognosis-related clinical characteristics. In summary, we have identified some m6A-lncRNAs that correlated with prognosis and tumor immune microenvironment in COAD. In addition, a potential alternative signature based on the expression of m6A-lncRNAs was provided for the management of COAD patients.